Share on StockTwits

Veracyte (NASDAQ:VCYT) Insider Christopher M. Hall sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $12.92, for a total transaction of $12,920.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

VCYT has been the subject of a number of recent research reports. Analysts at Leerink Swann cut their price target on shares of Veracyte from $23.00 to $20.00 in a research note on Thursday, August 14th. They now have an “outperform” rating on the stock. Separately, analysts at Janney Montgomery Scott initiated coverage on shares of Veracyte in a research note on Thursday, June 26th. They set a “buy” rating and a $25.00 price target on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Veracyte in a research note on Thursday, June 19th. They set an “overweight” rating and a $21.00 price target on the stock. Six research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $20.80.

Shares of Veracyte (NASDAQ:VCYT) opened at 12.57 on Friday. Veracyte has a 52 week low of $10.88 and a 52 week high of $19.00. The stock has a 50-day moving average of $14.28 and a 200-day moving average of $14.90. The company’s market cap is $270.1 million.

Veracyte (NASDAQ:VCYT) last released its earnings data on Wednesday, August 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.02. The company had revenue of $8.70 million for the quarter, compared to the consensus estimate of $9.36 million. On average, analysts predict that Veracyte will post $-1.30 earnings per share for the current fiscal year.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.